Clinical trial
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With…
NCT00324987 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00324987 |
|---|---|
| Title | Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor |
| Official title | A Phase III Randomized Study of Imatinib, With or Without Bevacizumab (NSC-704865), in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors |
| Acronym | S0502 |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumor |
| Intervention type | Biological, Drug, Other |
| Interventions | Bevacizumab, Imatinib Mesylate, Laboratory Biomarker Analysis, Pharmacological Study |
| Enrollment | 12 |
| Start date | Apr 1, 2008 |
| Primary completion | Jul 1, 2015 |
| Completion | Jul 1, 2015 |
| First posted | May 11, 2006 |
| Last update posted | Sep 14, 2017 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: